A Phase 3 interventional study of Saxagliptin and Dapagliflozin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 79 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2018-06-01.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment, is one of 10 that started in 2014, is one of 27 in phase 3, and was the 56th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 77th largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 119 in phase 3, and was the 240th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the enrollment visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
Drug: Saxagliptin · Drug: Dapagliflozin · Drug: Placebo matching with Saxagliptin · Drug: Placebo matching with Dapagliflozin
Sitagliptin 100 mg and matching placebo 0 mg (once daily)
Drug: Sitagliptin · Drug: Placebo matching with Sitagliptin
administered orally once daily
administered orally once daily
administered orally once daily
administered orally once daily
administered orally once daily
administered orally once daily
Mean Change in HbA1c
Time frame: Baseline (randomization) to Week 26
Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%
Time frame: week 26
Mean Change in Total Body Weight
Time frame: Baseline (randomization) to Week 26
Mean Change in Fasting Plasma Glucose (FPG)
Time frame: Baseline (randomization) to Week 26
461 Patients were Randomized into the study, 411 patients completed the 26 weeks part. Out of them 402 patients continued into the additional 26 week part. Out of them 378 patients completed the 52 weeks period (26+26 weeks).
| Milestone | SAXA + DAPA + MET | SITA + MET |
|---|---|---|
| Started | 232 | 229 |
| Completed | 213 | 198 |
| Not completed | 19 | 31 |
| Withdrew: Adverse event | 1 | 9 |
| Withdrew: Discontinuation by the subject | 2 | 2 |
| Withdrew: Withrawal of the consent by the subject | 7 | 10 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Subject no longer meets study criteria | 5 | 8 |
| Withdrew: Other | 1 | 1 |
| Milestone | SAXA + DAPA + MET | SITA + MET |
|---|---|---|
| Started | 209 | 193 |
| Completed | 198 | 180 |
| Not completed | 11 | 13 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Subject no longer meets study criteria | 0 | 1 |
| Withdrew: Withrawal of the consent by the subject | 4 | 6 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Non-compliance | 2 | 3 |
| percentage (%) | Saxagliptin + Dapagliflozin + Metformin Group | SITA + MET |
|---|---|---|
| Mean Change in HbA1c | -1.41 ± 0.0696 | -1.07 ± 0.0719 |
| Percentage of subjects | Saxagliptin + Dapagliflozin + Metformin Group | SITA + MET |
|---|---|---|
| Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0% | 37.3 ± 3.150 | 25.1 ± 2.871 |
| kg | Saxagliptin + Dapagliflozin + Metformin Group | SITA + MET |
|---|---|---|
| Mean Change in Total Body Weight | -1.86 ± 0.2010 | -0.51 ± 0.2078 |
| mg/dl | Saxagliptin + Dapagliflozin + Metformin Group | SITA + MET |
|---|---|---|
| Mean Change in Fasting Plasma Glucose (FPG) | -31.9 ± 2.538 | -11.0 ± 2.668 |
Collected over 52 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAXA + DAPA + MET | 0/232 (0%) | 9/232 (3.9%) | 112/232 (48.3%) |
| Sita + Met | 0/229 (0%) | 13/229 (5.7%) | 123/229 (53.7%) |
| Event | SAXA + DAPA + MET | Sita + Met |
|---|---|---|
| ENDOMETRIOSISReproductive system and breast disorders | 0/232 | 2/229 |
| PNEUMONIAInfections and infestations | 0/232 | 2/229 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/232 | 2/229 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/232 | 1/229 |
| CARDIAC FAILURE CHRONICCardiac disorders | 0/232 | 1/229 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/232 | 1/229 |
| CONGESTIVE CARDIOMYOPATHYCardiac disorders | 0/232 | 1/229 |
| MITRAL VALVE PROLAPSECardiac disorders | 0/232 | 1/229 |
| TACHYCARDIACardiac disorders | 0/232 | 1/229 |
| ABDOMINAL PAINGastrointestinal disorders | 0/232 | 1/229 |
| Event | SAXA + DAPA + MET | Sita + Met |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 18/232 | 12/229 |
| HEADACHENervous system disorders | 13/232 | 10/229 |
| INFLUENZAInfections and infestations | 8/232 | 11/229 |
| URINARY TRACT INFECTIONRenal and urinary disorders | 10/232 | 7/229 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/232 | 9/229 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 7/232 | 8/229 |
| HYPERTENSIONVascular disorders | 3/232 | 8/229 |
| BRONCHITISInfections and infestations | 8/232 | 2/229 |
| COUGHRespiratory, thoracic and mediastinal disorders | 3/232 | 7/229 |
| ANAEMIABlood and lymphatic system disorders | 1/232 | 7/229 |
| Age, Continuous(years) | SAXA + DAPA + MET | SITA + MET | Total |
|---|---|---|---|
| Mean | 55.9 ± 8.87 | 55.8 ± 9.55 | 55.9 ± 9.21 |
| Sex: Female, Male(Participants) | SAXA + DAPA + MET | SITA + MET | Total |
|---|---|---|---|
| Female | 132 | 119 | 251 |
| Male | 100 | 110 | 210 |
| Region of Enrollment(participants) | SAXA + DAPA + MET | SITA + MET | Total |
|---|---|---|---|
| Europe | 72 | 74 | 146 |
| North America | 114 | 113 | 227 |
| Central America | 46 | 42 | 88 |
Ran from Sep 2014 to primary completion in Sep 2016, 24 months.
Results were first posted in Jun 2018, 1 year 8 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Dapagliflozin · Sitagliptin